The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Aclaris Therapeutics, Inc. COM 00461U105   8,618,965 1,258,243 SH   SOLE   1,258,243 0 0
Compass Therapeutics, Inc. COM 20454B104   2,456,545 1,246,977 SH   SOLE   1,246,977 0 0
Disc Medicine, Inc. COM 254604101   11,440,241 243,513 SH   SOLE   243,513 0 0
Hims & Hers Health, Inc. COM CL A 433000106   23,482,966 3,733,381 SH   SOLE   3,733,381 0 0
Kinnate Biopharma Inc. COM 49705R105   4,936,340 3,525,957 SH   SOLE   3,525,957 0 0
Pharvaris N.V. COM N69605108   691,674 33,142 SH   SOLE   33,142 0 0
Theseus Pharmaceuticals, Inc. COM 88369M101   11,052,661 4,108,796 SH   SOLE   4,108,796 0 0